# Strategic Feedback — GPT-5.4 (R2)

**Role:** Journal editor (AER perspective)
**Model:** openai/gpt-5.4
**Timestamp:** 2026-03-30T10:58:57.941175
**Route:** OpenRouter + LaTeX
**Tokens:** 11717 in / 3368 out
**Response SHA256:** 8f4fa9ebecd1254e

---

## 1. THE ELEVATOR PITCH

This paper asks whether legal transparency mandates actually change scientific disclosure behavior. Using the fact that FDAAA 801 required Phase 2/3 clinical trials to report results but exempted Phase 1 trials, it studies whether mandatory disclosure increases the public reporting of trial outcomes, and whether the response is concentrated where enforcement is credible. A busy economist should care because this is not really about clinical trials per se; it is about whether disclosure regulation can mitigate selective reporting in the production of knowledge.

Does the paper articulate this pitch clearly in the first two paragraphs? Not quite. The current opening is vivid and informed, but it takes too long to get from “selective reporting is bad” to the actual economic question. The introduction is currently written like a public-health paper with an economics literature review attached, rather than an economics paper with a sharp question about incentives, regulation, and information production.

What the first two paragraphs should say instead:

> Selective disclosure is a central problem in markets for information: when producers can choose what to reveal, the public evidence base becomes systematically biased. Clinical trials are an extreme case, because suppressed or selectively reported results distort medical decision-making and waste research spending. Policymakers have increasingly responded with transparency mandates, but we know remarkably little about a basic question: do disclosure mandates actually change reporting behavior, and under what conditions do they bite?
>
> This paper studies that question using FDAAA 801, which required Phase 2/3 clinical trials to register and report results on ClinicalTrials.gov while exempting Phase 1 trials. Comparing reporting behavior across trial phases before and after the law, I show that mandatory disclosure is associated with more public reporting, with effects concentrated among industry-sponsored and US-linked trials where enforcement is most credible. The broad lesson is that transparency rules can change the supply of public information, but mainly when they are backed by institutions that create real compliance incentives.

That is the paper’s best pitch. It turns the paper from “a DiD on clinical trial reporting” into “an economics paper about disclosure mandates in information markets.”

---

## 2. CONTRIBUTION CLARITY

**One-sentence contribution:**  
The paper provides evidence that mandatory disclosure regulation increases public reporting of clinical trial results, with effects concentrated in settings where enforcement is credible, suggesting that transparency mandates work through compliance incentives rather than norms alone.

### Is this contribution clearly differentiated from the closest 3-4 papers?
Only partially. The paper says it is the “first causal estimate,” which is a differentiator, but “first causal estimate” is not by itself an AER-level contribution unless the underlying substantive question is big and the answer changes how economists think. Right now the differentiation is mostly methodological relative to descriptive compliance papers. That is not enough. The paper needs to be clearer that existing medical papers document low compliance, while this paper asks a different question: whether legal disclosure rules alter the equilibrium supply of publicly observable scientific evidence, and where they do so.

### Is the contribution framed as answering a question about the world, or filling a gap in a literature?
It is mixed, but too often framed as filling a literature gap. The stronger version is clearly a world question: **Can governments force private actors to reveal inconvenient information, and does enforcement determine whether disclosure mandates matter?** That is a first-order economic question. The introduction should foreground that.

### Could a smart economist explain what’s new after reading the intro?
At the moment, they might say: “It’s a DiD paper on whether FDAAA increased trial reporting, with bigger effects for industry.” That is not distinctive enough. You want them to say: “It shows that disclosure mandates in science only move behavior where enforcement is real, which has implications for publication bias, pre-registration, and the design of information regulation more generally.”

### What would make this contribution bigger?
A few concrete possibilities:

1. **Make the object of interest the evidence base, not just trial-level reporting.**  
   Right now the outcome is “did the trial post results?” That is sensible, but narrow. The bigger contribution would connect to what happened to the publicly observable stock of evidence: for example, whether more null or unfavorable evidence enters the public record, whether timing changes, or whether the composition of reported findings changes. That would elevate the paper from compliance to information production.

2. **Lean harder into enforcement as the core concept.**  
   The industry/non-industry split is probably the most interesting part of the paper strategically. If the paper can convincingly frame itself around where mandates bite, the contribution becomes “when does disclosure regulation work?” rather than “did this law matter on average?”

3. **Connect more directly to economics and social science transparency.**  
   The current discussion makes a quick leap to economics pre-registration, but it feels tacked on. If the author wants this to matter beyond health, the paper needs a tighter bridge: mandated registry with penalties versus voluntary registry without penalties; legal enforceability versus reputational norms; external validity to research transparency generally.

4. **Use a more policy-relevant comparison.**  
   The paper repeatedly says the effect is concentrated where enforcement is plausible. That suggests the real comparison is not just treated vs exempt, but high-enforcement vs low-enforcement exposure. If that becomes the narrative center, the paper gets larger.

---

## 3. LITERATURE POSITIONING

### Closest neighbors
The closest papers and literatures seem to be:

- **Anderson et al. (2015)** on compliance with results reporting at ClinicalTrials.gov.
- **Prayle, Hurley, and Smyth (2012)** on compliance with mandatory reporting requirements.
- **DeVito et al. (2020)** on trends in trial transparency/compliance.
- **Turner et al. (2008)** on selective publication of antidepressant trials.
- On the economics side, more conceptually:
  - **Dranove and Jin (2010)** or related work on quality disclosure/report cards.
  - **Jin and Leslie (2003/2009-ish disclosure/quality signaling line)** depending what exactly they cite.
  - **Olken (2015)** and **Nosek et al. (2015)** for pre-analysis/pre-registration logic.
  - **Christensen, Miguel, and others** on transparency in economics.

### How should the paper position itself relative to those neighbors?
It should **build on** the medical compliance literature and **translate** it into an economics question. It should not “attack” those papers; they are doing descriptive measurement, and this paper asks a different question. The right positioning is:

- The medical literature established that compliance is incomplete.
- This paper asks whether the legal mandate changed behavior relative to an exempt group, and whether responses track enforcement incentives.
- The economics contribution is to interpret trial transparency as a disclosure-regulation problem in a market for information.

That is a cleaner and more ambitious conversation.

### Is it positioned too narrowly or too broadly?
At present, oddly, both.

- **Too narrowly** in the empirical setup: it reads like a specific institutional paper about one clause of one law.
- **Too broadly** in the claims: it gestures toward the replication crisis, economics pre-registration, and scientific credibility in general without fully earning that reach.

The fix is to choose one strong frame: **disclosure mandates and enforcement in the production of evidence.** That is broad enough to matter, but anchored enough to be credible.

### What literature does the paper seem unaware of?
It needs deeper engagement with at least four conversations:

1. **Disclosure regulation and mandatory information revelation** in IO, finance, health care, and public economics.
2. **Bureaucratic/legal enforcement**—papers on when rules without active penalties still matter because of downstream approval, procurement, or reputational channels.
3. **Science as an economic institution**—the incentives that govern knowledge production and dissemination.
4. **Publication bias / selective reporting as market design**, not just as a norm violation.

### Is the paper having the right conversation?
Not yet. It is currently having a hybrid conversation: public health + transparency in economics. The more impactful framing is the unexpected bridge: **clinical trial registries as a laboratory for the economics of disclosure in scientific production.** That is the right conversation for AER readers.

---

## 4. NARRATIVE ARC

### Setup
Before the paper, selective reporting distorts the scientific record. Policymakers responded with registration and reporting mandates, but it is unclear whether these mandates meaningfully alter disclosure behavior or merely create nominal rules with low compliance.

### Tension
Disclosure mandates are only as strong as the incentives behind them. A law on the books may not matter if enforcement is weak, and voluntary transparency norms may not solve the file-drawer problem. So the central puzzle is whether transparency regulation changes actual behavior, and whether it does so broadly or only where noncompliance is costly.

### Resolution
The paper finds that mandatory reporting is associated with more public disclosure, but the action is concentrated among industry-sponsored and US-linked trials. The implied resolution is that disclosure mandates can work, but largely through credible enforcement rather than general norm shifts.

### Implications
This would imply that the design of transparency policy matters: mandates without enforcement may produce little change, and voluntary pre-registration regimes may have limited bite. More broadly, the production of public knowledge is shaped by institutional incentives, not just scientific norms.

### Does the paper have a clear narrative arc?
It has the ingredients, but the arc is not yet well executed. Right now it reads too much like:
1. Here is why selective reporting is bad.
2. Here is a law.
3. Here is a DiD.
4. Main estimate.
5. Complication.
6. Heterogeneity.
7. Discussion.

The most promising story is actually:

- **Setup:** science suffers from selective disclosure.
- **Tension:** policymakers use transparency mandates, but nobody knows whether mandates change disclosure absent enforcement.
- **Resolution:** they do, but only where enforcement is credible.
- **Implication:** disclosure policy and research transparency should be understood through incentives, not moral exhortation.

That story is in the paper, but it is not the paper’s organizing spine. The paper should tell that story from the first page and let every section serve it.

One big issue: the paper currently undercuts its own central finding early and often. Intellectual honesty is good, but strategically the author is letting the caveat become the story. The story should not be “I found a result, but maybe it’s not causal.” The story should be “the economically meaningful pattern is that reporting responds where compliance incentives are strongest.” That is the narrative asset here.

---

## 5. THE “SO WHAT?” TEST

### What fact would I lead with at a dinner party of economists?
“I’ve got a paper showing that trial transparency mandates only really move reporting where enforcement is credible—industry sponsors respond a lot, academia basically doesn’t.”

That is the hook, not the pooled 10 percentage point estimate.

### Would people lean in or reach for their phones?
Some would lean in, especially economists interested in information, health, law and economics, or science policy. But many would tune out if it is presented as a narrow clinical-trials compliance study. The paper’s fate depends heavily on framing.

### What follow-up question would they ask?
Almost certainly: “So is this about transparency mandates generally, or just about firms responding to the FDA approval process?” That is exactly the right question, and the paper should be built to answer it conceptually.

### If findings are modest or complicated, is that still interesting?
Yes, but only if the paper makes the right case. The interesting result is not “the average estimate is modest and complicated.” The interesting result is “mandates without teeth may do very little.” That is valuable and policy relevant. If framed poorly, it will feel like a compliance paper with imperfect design. If framed well, it becomes a paper about the limits of transparency policy.

---

## 6. STRUCTURAL SUGGESTIONS

### What would make it read better?

1. **Rewrite the first three pages around one question.**  
   Right now the introduction spends too much space on examples of selective reporting and too little on the paper’s actual economic question. Tighten the motivation and get to the question and answer faster.

2. **Move “first causal estimate” out of center stage.**  
   That is a supporting point, not the headline. The headline is about disclosure mandates and enforcement.

3. **Front-load the heterogeneity result.**  
   Strategically, the industry/non-industry split is the paper’s most interesting fact. It should appear in the abstract, introduction, and maybe even as the lead empirical result after a concise average effect. Right now it comes too late.

4. **Shrink the institutional background.**  
   The background is competent but long relative to what it buys. AER readers do not need this much exposition unless the institutional details are doing conceptual work.

5. **Either deepen or drop the “primary outcomes” mechanism section.**  
   In its current form, it feels underpowered conceptually. The interpretation is ambiguous, and it distracts from the stronger reporting/enforcement story. Unless the author can make this mechanism integral to the paper’s main thesis, I would demote it, shorten it, or move it to an appendix.

6. **Do not bury the paper’s own best line in the discussion.**  
   “Transparency mandates work only when backed by credible enforcement” is effectively the concluding thesis. It should appear much earlier and more prominently.

7. **The conclusion should do more than summarize.**  
   It should tell readers what they should now believe about disclosure policy, about scientific transparency, and about why voluntary norm-based reforms may underperform legal mandates with enforcement. Right now the conclusion is decent, but it could be sharper and more forward-looking.

### Are there results buried in robustness that belong in the main text?
Yes: the phase-specific pattern and especially the broader “dose-response” interpretation probably belong more centrally if the author wants an enforcement story. The placebo/pre-trend material obviously needs to be visible, but the paper should not let the robustness section become the only place where the more nuanced economic interpretation emerges.

---

## 7. WHAT WOULD MAKE THIS AN AER PAPER?

The gap is mostly **framing plus ambition**, with some **scope** concerns.

### Framing problem
Yes. The science is pitched too much as a compliance study in clinical trials, not enough as an economics paper about disclosure mandates, selective revelation, and enforcement. That is the biggest issue.

### Scope problem
Also yes. The outcome set is narrow, and the mechanism section is not yet doing enough work. For AER, the paper needs to feel like it teaches us something larger than “this one law increased this one registry outcome.”

### Novelty problem
Moderate. Mandatory transparency in trials is an important topic, but the baseline question—did FDAAA raise reporting?—is not by itself fresh enough for AER. What makes it fresher is the enforcement angle and the connection to information regulation more broadly.

### Ambition problem
Yes. The paper is competent but safe. It does not yet fully exploit the bigger stakes of its own setting. The setting is excellent: scientific evidence production under disclosure regulation. The current manuscript undersells that.

### Single most impactful advice
**Reframe the paper around a broader claim: this is not a paper about clinical trial compliance; it is a paper about when disclosure mandates change the supply of public information, with credible enforcement—not transparency norms—the central mechanism.**

If the author changes only one thing, it should be that.

---

### Strategic Assessment

- **Current framing quality:** Needs rethinking
- **Contribution clarity:** Somewhat fuzzy
- **Literature positioning:** Could be stronger
- **Narrative arc:** Serviceable
- **AER distance:** Medium-Far
- **Single biggest improvement:** Recast the paper as an economics paper on disclosure mandates and enforcement in information production, not as a narrow DiD study of ClinicalTrials.gov compliance.